Program
AK146D1
A development code. Also written as “AK146D1 for injection”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Transitional Cell, led by Akeso.
Furthest: phase 2, since May 9, 20264 company-led studies, 4 open or runningNext primary completion: Sep 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 44 open or running | phase 2since May 9, 2026 | Mar 16, 2025 | Sep 1, 2027phase 2 · NCT07591090 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 16, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06929663 · 166 planned · Australia
- Jun 18, 2025Phase 1 study in Advanced Solid TumorsNCT07067567 · 200 planned · China
- May 9, 2026Phase 2 study in Advanced Breast CancerPhase 2 reachedNCT07591090 · 200 planned · China
- Jun 4, 2026Phase 2 study in Carcinoma, Transitional CellNCT07636772 · 132 planned · China
Ahead
- Nov 5, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT07067567
- Sep 1, 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07591090
- Jun 30, 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT06929663
- Aug 24, 2028Primary completion: phase 2 study in Carcinoma, Transitional CellNCT07636772
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07636772Carcinoma, Transitional Cell · China | 2 | Not yet recruiting | Aug 24, 2028 | 132 |
| NCT07591090Advanced Breast Cancer · China | 2 | Recruiting | Sep 1, 2027 | 200 |
| NCT07067567Advanced Solid Tumors · China | 1 | Recruiting | Nov 5, 2026 | 200 |
| NCT06929663Advanced Solid Tumors · Australia | 1 | Recruiting | Jun 30, 2028 | 166 |
How it is read
Names in the registry
- “AK146D1 for injection”, 4 entries
Codes read as this program: AK146D1.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
- Carcinoma, Transitional Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.